Quarterly report · Q2
6095.TEDINET S100QPSY
Period2022-10-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.1bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥8.5bn | 2021-10-01 → 2022-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.4bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥717m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥867m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2021-10-01 → 2022-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥890m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥735m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥890m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥380m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥812m | 2021-10-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥599m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥391m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥618m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.5bn | at 2022-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥8.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2021-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥122m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥853m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥538m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.8bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥423m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥78m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4.2bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7m | 2021-10-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥17.42 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.62 | 2021-10-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.74 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.57 | 2022-01-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.05 | 2022-10-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥35.78 | 2021-10-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.26 | 2021-10-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 57.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-03-31 | −¥657m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥5.7bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥243m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥240m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥40m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥300,000 |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥94m |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| —segment total | revenue intersegment | 2022-10-01 → 2023-03-31 | ¥5m |
| —segment total | segment profit | 2022-10-01 → 2023-03-31 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2022-03-31 | −¥7m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2022-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥645m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥3.2bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥3.2bn |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Collective Intelligence Platformreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥202m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥199m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥30m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥1.0bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥1.0bn |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥3m |
| jpcrp040300-q2r_E30650-000Preventive Healthcare Platformreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥137m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥4.4bn |
| —segment total | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥7m |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.2419 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1776200 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0809 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1250000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0569 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 900000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0410 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 551200 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0251 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 542500 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0247 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 311532 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0142 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 300476 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0137 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 266800 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0122 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 264300 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0120 | |
| Number of shares held | CurrentQuarterInstant | 11474358 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5227 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 21918000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 219180 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 33690 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 21953590 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 219180 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 1900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 1900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 1900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 1900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0000 | |
| Cash and deposits | Prior1YearInstant | 6138758000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 5708116000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 1337650000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 2975816000 | JPY |
| Work in process | Prior1YearInstant | 30468000 | JPY |
| Work in process | CurrentQuarterInstant | 24920000 | JPY |
| Other ca | Prior1YearInstant | 206338000 | JPY |
| Other ca | CurrentQuarterInstant | 292878000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -766000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | － | JPY |
| Current assets | Prior1YearInstant | 7712448000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |